- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00412984
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)
5 juin 2018 mis à jour par: Bristol-Myers Squibb
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
20976
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Bloemfontein
-
Westdene, Bloemfontein, Afrique du Sud, 9301
- Local Institution
-
-
Cape Town
-
Observatory, Cape Town, Afrique du Sud, 7925
- Local Institution
-
-
Gauteng
-
Pretoria, Gauteng, Afrique du Sud, 0084
- Local Institution
-
Pretoria, Gauteng, Afrique du Sud, 0132
- Local Institution
-
-
KWA ZULU Natal
-
Richards Bay, KWA ZULU Natal, Afrique du Sud, 3900
- Local Institution
-
-
Western CAPE
-
Bellville Cape Town, Western CAPE, Afrique du Sud, 7530
- Local Institution
-
George, Western CAPE, Afrique du Sud, 6529
- Local Institution
-
Parow, Western CAPE, Afrique du Sud, 7505
- Local Institution
-
Somerset West, Western CAPE, Afrique du Sud, 7130
- Local Institution
-
Worcester, Western CAPE, Afrique du Sud, 6850
- Local Institution
-
-
-
-
-
Aachen, Allemagne, 52074
- Local Institution
-
Bad Krozingen, Allemagne, 79189
- Local Institution
-
Bad Neustadt/ Salle, Allemagne, 97616
- Local Institution
-
Bad Oeynhausen, Allemagne, 32545
- Local Institution
-
Berlin, Allemagne, 13353
- Local Institution
-
Berlin, Allemagne, 14050
- Local Institution
-
Berlin, Allemagne, 10787
- Local Institution
-
Berlin, Allemagne, 10789
- Local Institution
-
Berlin, Allemagne, 12043
- Local Institution
-
Berlin-Kopenick, Allemagne, 12559
- Local Institution
-
Betzdorf, Allemagne, 57518
- Local Institution
-
Bochum, Allemagne, 44791
- Local Institution
-
Bochum, Allemagne, 44789
- Local Institution
-
Bonn, Allemagne, 53127
- Local Institution
-
Coburg, Allemagne, 96450
- Local Institution
-
Dillingen, Allemagne, 66763
- Local Institution
-
Dresden, Allemagne, 01099
- Local Institution
-
Duisburg, Allemagne, 47139
- Local Institution
-
Essen, Allemagne, 45122
- Local Institution
-
Frankfurt Am Main, Allemagne, 60594
- Local Institution
-
Gottingen, Allemagne, 37075
- Local Institution
-
Halle/Saale, Allemagne, 06120
- Local Institution
-
Hannover, Allemagne, 30625
- Local Institution
-
Heidelberg, Allemagne, 69120
- Local Institution
-
Heidelberg, Allemagne, 69115
- Local Institution
-
Kassel, Allemagne, 34121
- Local Institution
-
Lahr, Allemagne, 77933
- Local Institution
-
Ludwigshafen, Allemagne, 67063
- Local Institution
-
Ludwigshafen, Allemagne, 67073
- Local Institution
-
Mannheim, Allemagne, 68167
- Local Institution
-
Marburg, Allemagne, 35043
- Local Institution
-
Munchen, Allemagne, 81675
- Local Institution
-
Munchen, Allemagne, 80636
- Local Institution
-
Munchen, Allemagne, 81545
- Local Institution
-
Osnabruck, Allemagne, 49076
- Local Institution
-
Regensburg, Allemagne, 93053
- Local Institution
-
Riesa, Allemagne, D-01587
- Local Institution
-
Rostiock, Allemagne, 18057
- Local Institution
-
Trier, Allemagne, 54292
- Local Institution
-
Waren, Allemagne, 17192
- Local Institution
-
Witten, Allemagne, 58455
- Local Institution
-
Wolmirstedt, Allemagne, 39326
- Local Institution
-
Worms, Allemagne, 67550
- Local Institution
-
-
-
-
-
Buenos Aires, Argentine, 1119
- Local Institution
-
Buenos Aires, Argentine, C1280AEB
- Local Institution
-
Buenos Aires, Argentine, 1181
- Local Institution
-
Buenos Aires, Argentine, C1426ANZ
- Local Institution
-
Buenos Aires, Argentine, 1280
- Local Institution
-
Cordoba, Argentine, 5000
- Local Institution
-
Cordoba, Argentine, X5000EPU
- Local Institution
-
Cordoba, Argentine, X5008KKF
- Local Institution
-
Cordoba, Argentine, X5003DCE
- Local Institution
-
Salta, Argentine, 4400
- Local Institution
-
Santa Fe, Argentine, 3000
- Local Institution
-
Tucuman, Argentine, T4000NIL
- Local Institution
-
-
Buenos Aires
-
Adrogue, Buenos Aires, Argentine, 1846
- Local Institution
-
Bahia Blanca, Buenos Aires, Argentine, B8000FTD
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, CP1425A WC
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, 1128AAD
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, 1128
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, 1426 EGR
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, C1426 EGR
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentine, CP1425AWC
- Local Institution
-
Ciudad Autonoma De, Buenos Aires, Argentine, 1180
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentine, CI094AAD
- Local Institution
-
Coronel Suarez, Buenos Aires, Argentine, B7540GHD
- Local Institution
-
Haedo, Buenos Aires, Argentine, B1706AJU
- Local Institution
-
Junin, Buenos Aires, Argentine, 6000
- Local Institution
-
La Plata, Buenos Aires, Argentine, 1900
- Local Institution
-
La Plata, Buenos Aires, Argentine, B1900AXI
- Local Institution
-
La Plata, Buenos Aires, Argentine, 1902
- Local Institution
-
Mar Del Plata, Buenos Aires, Argentine, 7600
- Local Institution
-
Merlo, Buenos Aires, Argentine, B1722COV
- Local Institution
-
Merlo, Buenos Aires, Argentine, 1722
- Local Institution
-
Olivos, Buenos Aires, Argentine, 1602
- Local Institution
-
Quilmes, Buenos Aires, Argentine, 1878
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentine, B1704ESN
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentine, B1704ETD
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentine, 1706
- Local Institution
-
San Justo, Buenos Aires, Argentine, 1754
- Local Institution
-
San Martin, Buenos Aires, Argentine, 1650
- Local Institution
-
San Nicolas, Buenos Aires, Argentine, 2900
- Local Institution
-
Zarate, Buenos Aires, Argentine, 2800
- Local Institution
-
Zarate, Buenos Aires, Argentine, B2800DGH
- Local Institution
-
-
Provincia DE Cordoba
-
Cordoba, Provincia DE Cordoba, Argentine, 5000
- Local Institution
-
-
RIO Negro
-
Cipolletti, RIO Negro, Argentine, 8324
- Local Institution
-
-
Santa FE
-
Rosario, Santa FE, Argentine, 2000
- Local Institution
-
Rosario, Santa FE, Argentine, S2000CVB
- Local Institution
-
Rosario, Santa FE, Argentine, S2001ODA
- Local Institution
-
-
Santa Fe
-
Rosario, Santa Fe, Argentine, S2000CVD
- Local Institution
-
Rosario, Santa Fe, Argentine, S2000 CVD
- Local Institution
-
-
Tucuman
-
San Miquel De Tucuman, Tucuman, Argentine, 4000
- Local Institution
-
-
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australie, 2450
- Local Institution
-
Concord, New South Wales, Australie, 2139
- Local Institution
-
Gosford, New South Wales, Australie, 2250
- Local Institution
-
Kogarah, New South Wales, Australie, 2217
- Local Institution
-
Miranda, New South Wales, Australie, 2228
- Local Institution
-
-
Queensland
-
Auchenflower, Queensland, Australie, 4066
- Local Institution
-
Brisbane, Queensland, Australie, 4032
- Local Institution
-
Caboolture, Queensland, Australie, 4510
- Local Institution
-
Herston, Queensland, Australie, 4029
- Local Institution
-
Kippa Ring, Queensland, Australie, 4021
- Local Institution
-
Nambour, Queensland, Australie, 4560
- Local Institution
-
Sherwood, Queensland, Australie, 4075
- Local Institution
-
-
South Australia
-
Adelaide, South Australia, Australie, SA 5000
- Local Institution
-
Ashford, South Australia, Australie, 5035
- Local Institution
-
Bedford Park, South Australia, Australie, 5042
- Local Institution
-
Woodville, South Australia, Australie, 5011
- Local Institution
-
-
Victoria
-
Box Hill, Victoria, Australie, 3128
- Local Institution
-
Dandenong, Victoria, Australie, 3175
- Local Institution
-
Geelong, Victoria, Australie, 3220
- Local Institution
-
-
Western Australia
-
Fremantle, Western Australia, Australie, 6160
- Local Institution
-
Joondalup, Western Australia, Australie, 6027
- Local Institution
-
-
-
-
-
Aalst, Belgique, 9300
- Local Institution
-
Antwerpen, Belgique, 2020
- Local Institution
-
Antwerpen, Belgique, 2060
- Local Institution
-
Arlon, Belgique, 6700
- Local Institution
-
Brugge, Belgique, 8000
- Local Institution
-
Brussels, Belgique, 1090
- Local Institution
-
Dillingen, Belgique, 66763
- Local Institution
-
Genk, Belgique, 3600
- Local Institution
-
Gent, Belgique, 9000
- Local Institution
-
Gilly, Belgique, 6060
- Local Institution
-
Hasselt, Belgique, 3500
- Local Institution
-
Huy, Belgique, 4500
- Local Institution
-
Kortrijk, Belgique, 8500
- Local Institution
-
Menen, Belgique, 8930
- Local Institution
-
Mol, Belgique, 2400
- Local Institution
-
Montegnee, Belgique, 4420
- Local Institution
-
Verviers, Belgique, 4800
- Local Institution
-
Woluwe- Saint Lambert, Belgique, 1200
- Local Institution
-
Yvoir, Belgique, 5530
- Local Institution
-
-
-
-
-
Rio De Janeiro, Brésil, 20551
- Local Institution
-
Rio De Janeiro, Brésil, 20551-030
- Local Institution
-
Rio De Janeiro, Brésil, 22251-030
- Local Institution
-
Rio De Janeiro, Brésil, 22251
- Local Institution
-
Sao Paulo, Brésil, 01323-010
- Local Institution
-
Sao Paulo, Brésil, 01323
- Local Institution
-
Sao Paulo, Brésil, 04012
- Local Institution
-
Sao Paulo, Brésil, 04024-002
- Local Institution
-
Sao Paulo, Brésil, 04038
- Local Institution
-
Sao Paulo, Brésil, 01221-900
- Local Institution
-
Sao Paulo, Brésil, 01221
- Local Institution
-
Sao Paulo, Brésil, 01322-001
- Local Institution
-
Sao Paulo, Brésil, 01322
- Local Institution
-
Sao Paulo, Brésil, 01323-001
- Local Institution
-
Sao Paulo, Brésil, 04012-180
- Local Institution
-
Sao Paulo, Brésil, 04024
- Local Institution
-
Sao Paulo, Brésil, 04038-031
- Local Institution
-
Sao Paulo, Brésil, 08270-070
- Local Institution
-
Sao Paulo, Brésil, 08270
- Local Institution
-
-
Bahia
-
Salvador, Bahia, Brésil, 40144
- Local Institution
-
Salvador, Bahia, Brésil, 41810
- Local Institution
-
Salvador, Bahia, Brésil, 40144-900
- Local Institution
-
Salvador, Bahia, Brésil, 41810-010
- Local Institution
-
-
Minas Gerais
-
Belo Horzonte, Minas Gerais, Brésil, 30150-221
- Local Institution
-
Belo Horzonte, Minas Gerais, Brésil, 30150
- Local Institution
-
Juiz De Fora, Minas Gerais, Brésil, 36021-630
- Local Institution
-
Juiz De Fora, Minas Gerais, Brésil, 36021
- Local Institution
-
Uberaba, Minas Gerais, Brésil, 38056 055
- Local Institution
-
Uberlandia, Minas Gerais, Brésil, 38400-299
- Local Institution
-
Uberlandia, Minas Gerais, Brésil, 38400
- Local Institution
-
-
Para
-
Belem, Para, Brésil, 66087-660
- Local Institution
-
Belem, Para, Brésil, 66087
- Local Institution
-
-
Parana
-
Campina Grande Do Sul, Parana, Brésil, 83430-000
- Local Institution
-
Campina Grande Do Sul, Parana, Brésil, 83430
- Local Institution
-
Curitiba, Parana, Brésil, 80010
- Local Institution
-
Curitiba, Parana, Brésil, 80730
- Local Institution
-
Curitiba, Parana, Brésil, 80010-030
- Local Institution
-
Curitiba, Parana, Brésil, 80730-150
- Local Institution
-
Londrina, Parana, Brésil, 86010-450
- Local Institution
-
Londrina, Parana, Brésil, 86010
- Local Institution
-
-
RIO Grande DO Norte
-
Natal, RIO Grande DO Norte, Brésil, 59020-100
- Local Institution
-
-
RIO Grande DO SUL
-
Porte Alegre, RIO Grande DO SUL, Brésil, 90610-000
- Local Institution
-
Porte Alegre, RIO Grande DO SUL, Brésil, 90880-480
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brésil, 90035-903
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brésil, 90020-090
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brésil, 90620-001
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brésil, 91350-280
- Local Institution
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brésil, 59020
- Local Institution
-
-
Rio Grande Do Sul
-
Porte Alegre, Rio Grande Do Sul, Brésil, 90610
- Local Institution
-
Porte Alegre, Rio Grande Do Sul, Brésil, 90880480
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brésil, 90035
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brésil, 90020
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brésil, 90620
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brésil, 91350
- Local Institution
-
-
SAO Paulo
-
Botucatu, SAO Paulo, Brésil, 18618-000
- Local Institution
-
Campinas, SAO Paulo, Brésil, 13059-740
- Local Institution
-
Marilia, SAO Paulo, Brésil, 17515-000
- Local Institution
-
Marilia, SAO Paulo, Brésil, 17515-460
- Local Institution
-
Marilia, SAO Paulo, Brésil, 17519-000
- Local Institution
-
San Jose Do Rio Preto, SAO Paulo, Brésil, 15090-000
- Local Institution
-
Santo Andre, SAO Paulo, Brésil, 09190-610
- Local Institution
-
Sao Jose Do Rio Preto, SAO Paulo, Brésil, 15015-750
- Local Institution
-
Sao Jose Do Rio Preto, SAO Paulo, Brésil, 15015-210
- Local Institution
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Brésil, 89010
- Local Institution
-
Blumenau, Santa Catarina, Brésil, 89010-500
- Local Institution
-
Sao Jose, Santa Catarina, Brésil, 88103
- Local Institution
-
Sao Jose, Santa Catarina, Brésil, 88103-450
- Local Institution
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brésil, 18618
- Local Institution
-
Campinas, Sao Paulo, Brésil, 13059
- Local Institution
-
Marilia, Sao Paulo, Brésil, 17519
- Local Institution
-
Marilia, Sao Paulo, Brésil, 17515
- Local Institution
-
San Jose Do Rio Preto, Sao Paulo, Brésil, 15090
- Local Institution
-
Santo Andre, Sao Paulo, Brésil, 09190
- Local Institution
-
Sao Jose Do Rio Preto, Sao Paulo, Brésil, 15015
- Local Institution
-
-
-
-
-
Quebec, Canada, G1J 1Z6
- Local Institution
-
-
Alberta
-
Calgary, Alberta, Canada, T2E 7C5
- Local Institution
-
Edmonton, Alberta, Canada, T6G 2B7
- Local Institution
-
Edmonton, Alberta, Canada, T5X 3N5
- Local Institution
-
Edmonton, Alberta, Canada, TSA 4L8
- Local Institution
-
Edmonton, Alberta, Canada, T56-3NJ
- Local Institution
-
-
British Columbia
-
Burnaby, British Columbia, Canada, V5G 1T4
- Local Institution
-
Nanaimo, British Columbia, Canada, V9R 3G9
- Local Institution
-
New Westminster, British Columbia, Canada, V3L 3W4
- Local Institution
-
North Vancouver, British Columbia, Canada, V7N 4M2
- Local Institution
-
Victoria, British Columbia, Canada, V8R 4R2
- Local Institution
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2V 4W3
- Local Institution
-
-
New Brunswick
-
Bathurst, New Brunswick, Canada, E2A 4X7
- Local Institution
-
-
Newfoundland and Labrador
-
Mount Pearl, Newfoundland and Labrador, Canada, A1N 1W7
- Local Institution
-
St Johns, Newfoundland and Labrador, Canada, A1B 3V6
- Local Institution
-
St. John'S, Newfoundland and Labrador, Canada, A1A 3R5
- Local Institution
-
St. John'S, Newfoundland and Labrador, Canada, A1E 2C2
- Local Institution
-
-
Ontario
-
Brampton, Ontario, Canada, L6Z 4N5
- Local Institution
-
Burlington, Ontario, Canada, L7M 4Y1
- Local Institution
-
Cambridge, Ontario, Canada, N1R 7R1
- Local Institution
-
Cambridge, Ontario, Canada, N1R 6V6
- Local Institution
-
Hamilton, Ontario, Canada, L8L 2X2
- Local Institution
-
London, Ontario, Canada, N6G 2V2
- Local Institution
-
Mississauga, Ontario, Canada, L5B 4A2
- Local Institution
-
Newmarket, Ontario, Canada, L3Y 5G8
- Local Institution
-
Newmarket, Ontario, Canada, L3Y 8C3
- Local Institution
-
Niagara Falls, Ontario, Canada, L2E 7H1
- Local Institution
-
Niagara Falls, Ontario, Canada, L2E7H1
- Local Institution
-
North Bay, Ontario, Canada, P1B 2H3
- Local Institution
-
Oshawa, Ontario, Canada, L1J 2J9
- Local Institution
-
Oshawa, Ontario, Canada, L1J 2K1
- Local Institution
-
Ottawa, Ontario, Canada, K1Y 4E9
- Local Institution
-
Ottawa, Ontario, Canada, K1Y 4W7
- Local Institution
-
Sarnia, Ontario, Canada, N7T 4X3
- Local Institution
-
Scarborough, Ontario, Canada, M1B 5N1
- Local Institution
-
Sudbury, Ontario, Canada, P3E 3B8
- Local Institution
-
Sudbury, Ontario, Canada, P3C 5K7
- Local Institution
-
Sudbury, Ontario, Canada, P3E 2N8
- Local Institution
-
Sudbury, Ontario, Canada, P3C5K7
- Local Institution
-
Toronto, Ontario, Canada, M9W 4L6
- Local Institution
-
Toronto, Ontario, Canada, M5B 1W8
- Local Institution
-
Weston, Ontario, Canada, M9N 1W4
- Local Institution
-
-
Prince Edward Island
-
Charlottetown, Prince Edward Island, Canada, C1A 5Y9
- Local Institution
-
-
Quebec
-
Drummondville, Quebec, Canada, J2B 7T1
- Local Institution
-
Greenfield Park, Quebec, Canada, J4V 2G8
- Local Institution
-
Lachine, Quebec, Canada, H8S 2E4
- Local Institution
-
Levis, Quebec, Canada, G6V 4Z5
- Local Institution
-
Longueuil, Quebec, Canada, J4K 1C8
- Local Institution
-
Longueuil, Quebec, Canada, J4N 0C9
- Local Institution
-
Longueuil, Quebec, Canada, J4N 1C2
- Local Institution
-
Montreal, Quebec, Canada, H3T 1E2
- Local Institution
-
Montreal, Quebec, Canada, H3A 1A1
- Local Institution
-
Montreal, Quebec, Canada, H1T 1C8
- Local Institution
-
Montreal, Quebec, Canada, H2W 1T8
- Local Institution
-
Montreal, Quebec, Canada, W3R-153
- Local Institution
-
Pointe- Claire, Quebec, Canada, H9R 3J1
- Local Institution
-
St-Lambert, Quebec, Canada, J4P 2H4
- Local Institution
-
Ste-Foy, Quebec, Canada, G1W 4R4
- Local Institution
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7L OY7
- Local Institution
-
-
-
-
LOS Lagos
-
Osorno, LOS Lagos, Chili, 5311089
- Local Institution
-
Osorno, LOS Lagos, Chili, 5311523
- Local Institution
-
-
Metropolitana
-
Santiago, Metropolitana, Chili, 7500520
- Local Institution
-
Santiago, Metropolitana, Chili, 7500922
- Local Institution
-
Santiago, Metropolitana, Chili, 8330074
- Local Institution
-
-
Region DE LA Araucania
-
Temuco, Region DE LA Araucania, Chili, 4781176
- Local Institution
-
-
Region De La Araucania
-
Temuco, Region De La Araucania, Chili, 4781156
- Local Institution
-
-
Valparaiso
-
Temuco, Valparaiso, Chili, 4781173
- Local Institution
-
Vina Del Mar, Valparaiso, Chili, 2570017
- Local Institution
-
-
-
-
Beijing
-
Beijing, Beijing, Chine, 100050
- Local Institution
-
Beijing, Beijing, Chine, 100001
- Local Institution
-
Beijing, Beijing, Chine, 100853
- Local Institution
-
Beijing, Beijing, Chine, 100020
- Local Institution
-
Beijing, Beijing, Chine, 100088
- Local Institution
-
Beijing, Beijing, Chine, 100101
- Local Institution
-
-
Gansu
-
Lanzhou, Gansu, Chine, 730000
- Local Institution
-
Lanzhou, Gansu, Chine, 730030
- Local Institution
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510080
- Local Institution
-
Guangzhou, Guangdong, Chine, 510120
- Local Institution
-
-
Hebei
-
Shijiazhuang, Hebei, Chine, 050000
- Local Institution
-
-
Heilongjiang
-
Daqing, Heilongjiang, Chine, 163001
- Local Institution
-
Haerbin, Heilongjiang, Chine, 150086
- Local Institution
-
Haerbin, Heilongjiang, Chine, 150001
- Local Institution
-
-
Hubei
-
Wuhan, Hubei, Chine, 430060
- Local Institution
-
-
Hunan
-
Changsha, Hunan, Chine, 410000
- Local Institution
-
-
Jiangsu
-
Hangzhou, Jiangsu, Chine, 310009
- Local Institution
-
Nanjing, Jiangsu, Chine, 210029
- Local Institution
-
-
Liaoning
-
Dalian, Liaoning, Chine, 116011
- Local Institution
-
Dalian, Liaoning, Chine, 116021
- Local Institution
-
Dalian, Liaoning, Chine, 116027
- Local Institution
-
Shenyang, Liaoning, Chine, 110016
- Local Institution
-
Shenyang, Liaoning, Chine, 110003
- Local Institution
-
-
Shandong
-
Jinan, Shandong, Chine, 250012
- Local Institution
-
Jinan, Shandong, Chine, 250033
- Local Institution
-
Qingdao, Shandong, Chine, 266011
- Local Institution
-
-
Shanghai
-
Shanghai, Shanghai, Chine, 200080
- Local Institution
-
Shanghai, Shanghai, Chine, 200025
- Local Institution
-
Shanghai, Shanghai, Chine, 200433
- Local Institution
-
Shanghai, Shanghai, Chine, 200011
- Local Institution
-
Shanghai, Shanghai, Chine, 200233
- Local Institution
-
Shanghai, Shanghai, Chine, 200003
- Local Institution
-
Shanghai, Shanghai, Chine, 100037
- Local Institution
-
Shanghai, Shanghai, Chine, 200031
- Local Institution
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Local Institution
-
Chongqing, Sichuan, Chine, 400010
- Local Institution
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310009
- Local Institution
-
-
-
-
-
Barranquilla, Colombie
- Local Institution
-
Barranquilla, Colombie, XXXXX
- Local Institution
-
Bogota, Colombie
- Local Institution
-
Bogota, Colombie, 000
- Local Institution
-
Cali, Colombie
- Local Institution
-
Medellin, Colombie
- Local Institution
-
-
Antioquia
-
Medellin, Antioquia, Colombie
- Local Institution
-
-
-
-
-
Busan, Corée, République de, 602-702
- Local Institution
-
Daegu, Corée, République de, 700-712
- Local Institution
-
Daegu, Corée, République de, 705-717
- Local Institution
-
Daejon, Corée, République de, 302-718
- Local Institution
-
Goyang, Corée, République de, 411-706
- Local Institution
-
Gwang Ju, Corée, République de, 501-757
- Local Institution
-
Gyeonggi, Corée, République de, 463-707
- Local Institution
-
Pusan, Corée, République de, 602-739
- Local Institution
-
Scongnam-Si, Corée, République de, 463-712
- Local Institution
-
Seoul, Corée, République de, 110-744
- Local Institution
-
Seoul, Corée, République de, 143-729
- Local Institution
-
Seoul, Corée, République de, 130-709
- Local Institution
-
Suwon, Corée, République de, 443-721
- Local Institution
-
-
Gyeonggi-Do
-
Anyang-Si, Gyeonggi-Do, Corée, République de, 431-070
- Local Institution
-
-
Korea
-
Incheon, Korea, Corée, République de, 400-711
- Local Institution
-
-
-
-
-
Arhus C, Danemark, 8000
- Local Institution
-
Esbjerg, Danemark, 6700
- Local Institution
-
Frederiksberg, Danemark, 2000
- Local Institution
-
Frederikssund, Danemark, 3600
- Local Institution
-
Gentofte, Danemark, 2900
- Local Institution
-
Haderslev, Danemark, 6100
- Local Institution
-
Hellerup, Danemark, 2900
- Local Institution
-
Herlev, Danemark, 2730
- Local Institution
-
Herning, Danemark, 7400
- Local Institution
-
Hillerod, Danemark, 3400
- Local Institution
-
Hvidovre, Danemark, 2650
- Local Institution
-
Kobenhavn, Danemark, 2100
- Local Institution
-
Kolding, Danemark, 6000
- Local Institution
-
Odense, Danemark, 5000
- Local Institution
-
Silkeborg, Danemark, 8600
- Local Institution
-
Slagelse, Danemark, 4200
- Local Institution
-
Svendborg, Danemark, 5700
- Local Institution
-
-
-
-
-
Albacete, Espagne, 02006
- Local Institution
-
Barcelona, Espagne, 08035
- Local Institution
-
Barcelona, Espagne, 08003
- Local Institution
-
Elda, Espagne, 03600
- Local Institution
-
Figueres, Espagne, 17600
- Local Institution
-
Gerona, Espagne, 17007
- Local Institution
-
Las Palmas, Espagne, 35010
- Local Institution
-
Madrid, Espagne, 28006
- Local Institution
-
Madrid, Espagne, 28046
- Local Institution
-
Madrid, Espagne, 28040
- Local Institution
-
Palma De Mallorca, Espagne, 07010
- Local Institution
-
San Sebastian De Los Reyes, Espagne, 28703
- Local Institution
-
Tarragona, Espagne, 43007
- Local Institution
-
Viladecans, Espagne, 08840
- Local Institution
-
-
Alicante
-
San Juan, Alicante, Espagne, 03550
- Local Institution
-
Torrevieja, Alicante, Espagne, 03186
- Local Institution
-
-
Almeria
-
La Canada, Almeria, Espagne, 04120
- Local Institution
-
-
Galicia
-
Lugo, Galicia, Espagne, 27003
- Local Institution
-
-
-
-
-
Helsinki, Finlande, 00280
- Local Institution
-
Helsinki, Finlande, FI-00280
- Local Institution
-
Hus, Finlande, 00029
- Local Institution
-
Jyvaskyla, Finlande, 40100
- Local Institution
-
Kemi, Finlande, 94100
- Local Institution
-
Oulu, Finlande, 90100
- Local Institution
-
Pori, Finlande, 28120
- Local Institution
-
Tampere, Finlande, 33100
- Local Institution
-
-
-
-
-
Amiens Cedex 1, France, 80054
- Local Institution
-
Bordeaux Cedex, France, 33075
- Local Institution
-
Brest, France, 29609
- Local Institution
-
Grenoble Cedex 09, France, 38043
- Local Institution
-
La Seyne Sur Mer, France, 83500
- Local Institution
-
Paris Cedex 18, France, 75018
- Local Institution
-
Six Fours Les Plages, France, 83140
- Local Institution
-
-
-
-
-
Chelyabinsk, Fédération Russe, 454136
- Local Institution
-
Chita, Fédération Russe, 672090
- Local Institution
-
Dzerzhinskiy, Fédération Russe, 140091
- Local Institution
-
Kazan, Fédération Russe, 420012
- Local Institution
-
Kemerovo, Fédération Russe, 650002
- Local Institution
-
Kirovsk, Fédération Russe, 187342
- Local Institution
-
Krasnodar, Fédération Russe, 350042
- Local Institution
-
Moscow, Fédération Russe, 119992
- Local Institution
-
Moscow, Fédération Russe, 125367
- Local Institution
-
Moscow, Fédération Russe, 109240
- Local Institution
-
Moscow, Fédération Russe, 105229
- Local Institution
-
Moscow, Fédération Russe, 111539
- Local Institution
-
Moscow, Fédération Russe, 115487
- Local Institution
-
Moscow, Fédération Russe, 115093
- Local Institution
-
Moscow, Fédération Russe, 121552
- Local Institution
-
Moscow, Fédération Russe, 117593
- Local Institution
-
Moscow, Fédération Russe, 127018
- Local Institution
-
Moscow, Fédération Russe, 125284
- Local Institution
-
Moscow, Fédération Russe, 111020
- Local Institution
-
Moscow, Fédération Russe, 119121
- Local Institution
-
Moscow, Fédération Russe, 121356
- Local Institution
-
Moscow, Fédération Russe, 117556
- Local Institution
-
Moscow, Fédération Russe, 119048
- Local Institution
-
Moscow, Fédération Russe, 123182
- Local Institution
-
Moscow, Fédération Russe, 125206
- Local Institution
-
Moscow, Fédération Russe, 125424
- Local Institution
-
Moscow, Fédération Russe, 129090
- Local Institution
-
Nizhni Novgorod, Fédération Russe, 603003
- Local Institution
-
Nizhni Novgorod, Fédération Russe, 603005
- Local Institution
-
Novosibirsk, Fédération Russe, 630008
- Local Institution
-
Novosibirsk, Fédération Russe, 630054
- Local Institution
-
Odintsovo, Fédération Russe, 143000
- Local Institution
-
Penza, Fédération Russe, 440026
- Local Institution
-
Perm, Fédération Russe, 614097
- Local Institution
-
Rostov-On-Don, Fédération Russe, 344022
- Local Institution
-
Ryazan, Fédération Russe, 390026
- Local Institution
-
Saint Petersburg, Fédération Russe, 193312
- Local Institution
-
Saint Petersburg, Fédération Russe, 193144
- Local Institution
-
Saint-Petersburg, Fédération Russe, 190103
- Local Institution
-
Saint-Petersburg, Fédération Russe, 191025
- Local Institution
-
Saint-Petersburg, Fédération Russe, 193163
- Local Institution
-
Saint-Petersburg, Fédération Russe, 196601
- Local Institution
-
Saint-Petersburg, Fédération Russe, 198013
- Local Institution
-
Samara, Fédération Russe, 443070
- Local Institution
-
Saratov, Fédération Russe, 410002
- Local Institution
-
St Petersburg, Fédération Russe, 198013
- Local Institution
-
St Petersburg, Fédération Russe, 192288
- Local Institution
-
St-Petersburg, Fédération Russe, 194354
- Local Institution
-
St-Petersburg, Fédération Russe, 195271
- Local Institution
-
St. Petersburg, Fédération Russe, 197341
- Local Institution
-
St. Petersburg, Fédération Russe, 197110
- Local Institution
-
St.-Petersburg, Fédération Russe, 197341
- Local Institution
-
St.Petersburg, Fédération Russe, 199106
- Local Institution
-
Tomsk, Fédération Russe, 634012
- Local Institution
-
Tumen, Fédération Russe, 625023
- Local Institution
-
Tver, Fédération Russe, 170036
- Local Institution
-
Voronezh, Fédération Russe, 394066
- Local Institution
-
Voronezh, Fédération Russe, 394065
- Local Institution
-
Yaroslavl, Fédération Russe, 150030
- Local Institution
-
Yaroslavl, Fédération Russe, 150003
- Local Institution
-
Yaroslavl, Fédération Russe, 150002
- Local Institution
-
Zheleznodorozhniy, Fédération Russe, 143920
- Local Institution
-
Zhukovsky, Fédération Russe, 140160
- Local Institution
-
Zhukovsky, Fédération Russe, 140180
- Local Institution
-
-
-
-
-
Hong Kong, Hong Kong
- Local Institution
-
Shatin, Hong Kong
- Local Institution
-
-
-
-
-
Budapest, Hongrie, 1125
- Local Institution
-
Budapest, Hongrie, 1023
- Local Institution
-
Budapest, Hongrie, 1032
- Local Institution
-
Budapest, Hongrie, 1096
- Local Institution
-
Budapest, Hongrie, 1085
- Local Institution
-
Debrecen, Hongrie, 4032
- Local Institution
-
Dunaujvaros, Hongrie, 2400
- Local Institution
-
Gyor, Hongrie, 9023
- Local Institution
-
Gyula, Hongrie, 5700
- Local Institution
-
Hodmezovasarhely, Hongrie, 6800
- Local Institution
-
Komarom, Hongrie, 2921
- Local Institution
-
Mosonmagyarovar, Hongrie, 9200
- Local Institution
-
Oroshaza, Hongrie, 5900
- Local Institution
-
Pecs, Hongrie, 7624
- Local Institution
-
Siofok, Hongrie, 8600
- Local Institution
-
Siofok, Hongrie, 8601
- Local Institution
-
Sopron, Hongrie, 9400
- Local Institution
-
Szentes, Hongrie, 6600
- Local Institution
-
Zalaegerszeg, Hongrie, 8900
- Local Institution
-
-
-
-
-
Ahmedabad, Inde, 380014
- Local Institution
-
Annamalainagar, Inde, 608002
- Local Institution
-
Bangalore, Inde, 560052
- Local Institution
-
Chennai, Inde, 600006
- Local Institution
-
Hyderabad, Inde, 500001
- Local Institution
-
Hyderabad, Inde, 500044
- Local Institution
-
Indore, Inde, 452014
- Local Institution
-
Indore, Inde, 452001
- Local Institution
-
Kolkata, Inde, 700054
- Local Institution
-
Kottayam, Inde, 686016
- Local Institution
-
Lucknow, Inde, 226003
- Local Institution
-
Mumbai Naka, Inde, 422005
- Local Institution
-
Nashik, Inde, 422002
- Local Institution
-
New Delhi, Inde, 110025
- Local Institution
-
New Delhi, Inde, 110060
- Local Institution
-
New Delhi, Inde, 116025
- Local Institution
-
Pune, Inde, 411001
- Local Institution
-
Pune, Inde, 411004
- Local Institution
-
Thrissur, Inde, 680002
- Local Institution
-
Vijayawada, Inde, 520008
- Local Institution
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, Inde, 530003
- Local Institution
-
-
Andhrapradesh
-
Visakhapatnam, Andhrapradesh, Inde, 530002
- Local Institution
-
-
Andra Pradesh
-
Hyderabad, Andra Pradesh, Inde, 500004
- Local Institution
-
-
Gujarat
-
Ahmedabad, Gujarat, Inde, 380060
- Local Institution
-
Vadodara, Gujarat, Inde, 390007
- Local Institution
-
-
Karnataka
-
Bangalore, Karnataka, Inde, 560054
- Local Institution
-
Bangalore, Karnataka, Inde, 5600034
- Local Institution
-
Bangalore, Karnataka, Inde, 560094
- Local Institution
-
Mysore, Karnataka, Inde, 570004
- Local Institution
-
-
Kerela
-
Calicut, Kerela, Inde, 673 004
- Local Institution
-
-
Maharashta
-
Pune, Maharashta, Inde, 411011
- Local Institution
-
-
Maharashtra
-
Nagpur, Maharashtra, Inde, 440010
- Local Institution
-
Nagpur, Maharashtra, Inde, 440012
- Local Institution
-
Pune, Maharashtra, Inde, 411001
- Local Institution
-
Pune, Maharashtra, Inde, 421006
- Local Institution
-
-
Punjab
-
Jalandhar, Punjab, Inde, 144008
- Local Institution
-
-
Rajasthan
-
Bikaner, Rajasthan, Inde, 334001
- Local Institution
-
Bikaner, Rajasthan, Inde, 334003
- Local Institution
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Inde, 226003
- Local Institution
-
-
-
-
-
Afula, Israël, 18101
- Local Institution
-
Ashkelon, Israël, 78306
- Local Institution
-
Givatayim, Israël, 53583
- Local Institution
-
Hadera, Israël, 38100
- Local Institution
-
Haifa, Israël, 31096
- Local Institution
-
Haifa, Israël, 34362
- Local Institution
-
Holon, Israël, 58100
- Local Institution
-
Jerusalem, Israël, 91120
- Local Institution
-
Jerusalem, Israël, 91240
- Local Institution
-
Kfar-Saba, Israël, 44281
- Local Institution
-
Nazareth, Israël, 16100
- Local Institution
-
Nazareth, Israël, 16000
- Local Institution
-
Petach-Tikva, Israël, 49100
- Local Institution
-
Safed, Israël, 13100
- Local Institution
-
Tel Aviv, Israël, 64239
- Local Institution
-
-
-
-
-
Ascoli Piceno, Italie, 63100
- Local Institution
-
Campobasso, Italie, 86100
- Local Institution
-
Chieti, Italie, 66013
- Local Institution
-
Cremona, Italie, 26100
- Local Institution
-
Fidenza (Pr), Italie, 43036
- Local Institution
-
Genova, Italie, 16132
- Local Institution
-
Isernia, Italie, 86170
- Local Institution
-
Livorno, Italie, 57100
- Local Institution
-
Milano, Italie, 20132
- Local Institution
-
Napoli, Italie, 80131
- Local Institution
-
Palermo, Italie, 90127
- Local Institution
-
Reggio Emilia, Italie, 42100
- Local Institution
-
Roma, Italie, 00168
- Local Institution
-
San Daniele De Friuli, Italie, 33038
- Local Institution
-
Torino, Italie, 10153
- Local Institution
-
Vittorio Veneto (Tv), Italie, 31029
- Local Institution
-
-
Lucca
-
Lido Di Camaiore, Lucca, Italie, 55043
- Local Institution
-
-
-
-
-
Fukui, Japon, 9100067
- Local Institution
-
Kagoshima, Japon, 8920822
- Local Institution
-
Kyoto, Japon, 6168152
- Local Institution
-
Nagasaki, Japon, 852-8102
- Local Institution
-
Oita, Japon, 8700033
- Local Institution
-
Osaka, Japon, 558-8558
- Local Institution
-
Osaka, Japon, 551-0032
- Local Institution
-
Osaka, Japon, 5510032
- Local Institution
-
Saga, Japon, 8490917
- Local Institution
-
-
Fukuoka
-
Itoshima City, Fukuoka, Japon, 819-1104
- Local Institution
-
Kurume, Fukuoka, Japon, 8390863
- Local Institution
-
Ohkawa-City, Fukuoka, Japon, 8310016
- Local Institution
-
-
Fukushima
-
Shirakawa City, Fukushima, Japon, 961-0005
- Local Institution
-
-
Gunma
-
Takasaki City, Gunma, Japon, 3700829
- Local Institution
-
-
Hokkaido
-
Asahikawa-Shi, Hokkaido, Japon, 0788214
- Local Institution
-
Katou-Gun, Hokkaido, Japon, 0800111
- Local Institution
-
Katou-gun, Hokkaido, Japon, 080111
- Local Institution
-
Sapporo-Shi, Hokkaido, Japon, 0028043
- Local Institution
-
Tomakomai-Shi, Hokkaido, Japon, 002-8043
- Local Institution
-
Tomakomai-shi, Hokkaido, Japon, 0028043
- Local Institution
-
Yubari, Hokkaido, Japon, 0680402
- Local Institution
-
-
Hyogo
-
Kobe, Hyogo, Japon, 6540026
- Local Institution
-
-
Kagoshima Prefecture
-
Izumi City, Kagoshima Prefecture, Japon, 8990131
- Local Institution
-
-
Kanagawa
-
Isehara, Kanagawa, Japon, 2591193
- Local Institution
-
Yokohama, Kanagawa, Japon, 2458575
- Local Institution
-
Yokohama City, Kanagawa, Japon, 2278501
- Local Institution
-
Yokosuka, Kanagawa, Japon, 2388567
- Local Institution
-
-
Miyagi
-
Sendai City, Miyagi, Japon, 983-8520
- Local Institution
-
-
Nara
-
Nara City, Nara, Japon, 630-8305
- Local Institution
-
-
Osaka
-
Izumi City, Osaka, Japon, 594-0071
- Local Institution
-
Osaka City, Osaka, Japon, 5330022
- Local Institution
-
Osaka-Shi, Osaka, Japon, 540-0006
- Local Institution
-
Osaka-shi, Osaka, Japon, 5400006
- Local Institution
-
Suita-City, Osaka, Japon, 5658565
- Local Institution
-
Takatsuki City, Osaka, Japon, 5690852
- Local Institution
-
Yao, Osaka, Japon, 5810036
- Local Institution
-
-
Saga
-
Saga City, Saga, Japon, 840-8571
- Local Institution
-
Saga City, Saga, Japon, 849-8501
- Local Institution
-
-
Saitama
-
Kasukabe-Shi, Saitama, Japon, 344-0035
- Local Institution
-
Kasukabe-shi, Saitama, Japon, 3440035
- Local Institution
-
-
Tokyo
-
Itabashi-Ku, Tokyo, Japon, 173-0015
- Local Institution
-
Itabashi-ku, Tokyo, Japon, 1730015
- Local Institution
-
Meguro-Ku, Tokyo, Japon, 153-8515
- Local Institution
-
Meguro-ku, Tokyo, Japon, 1538515
- Local Institution
-
Shinagawa-Ku, Tokyo, Japon, 1428666
- Local Institution
-
-
Toyama
-
Toyama City, Toyama, Japon, 9308550
- Local Institution
-
-
Yamaguchi
-
Iwakuni, Yamaguchi, Japon, 7400021
- Local Institution
-
-
-
-
-
Graz, L'Autriche, 8036
- Local Institution
-
Oberpullendorf, L'Autriche, 7350
- Local Institution
-
Vienna, L'Autriche, 1160
- Local Institution
-
-
-
-
-
Kuala Lumpur, Malaisie, 56000
- Local Institution
-
Kuala Lumpur, Malaisie, 59100
- Local Institution
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malaisie, 16150
- Local Institution
-
-
Sarawak
-
Kota Samarahan, Sarawak, Malaisie, 94300
- Local Institution
-
-
Selangor
-
Batu Caves, Selangor, Malaisie, 68100
- Local Institution
-
-
-
-
-
Puebla, Mexique, 11490
- Local Institution
-
Queretaro, Mexique, 76000
- Local Institution
-
-
BAJA California
-
Tijuana, BAJA California, Mexique, 22500
- Local Institution
-
-
Distrito Federal
-
Col. Toriello Guerra, Distrito Federal, Mexique, CP 14050
- Local Institution
-
Mexico City, Distrito Federal, Mexique, 06726
- Local Institution
-
Mexico City, Distrito Federal, Mexique, 14080
- Local Institution
-
Mexico City, Distrito Federal, Mexique, 07760
- Local Institution
-
Mexico City, Distrito Federal, Mexique, 06070
- Local Institution
-
Mexico City, Distrito Federal, Mexique, 10700
- Local Institution
-
-
Jalisco
-
Guadalajara, Jalisco, Mexique, 44200
- Local Institution
-
Guadalajara, Jalisco, Mexique, 44600
- Local Institution
-
Guadalajara, Jalisco, Mexique, 44656
- Local Institution
-
-
Michoacan
-
Morelia, Michoacan, Mexique, 58000
- Local Institution
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexique, 64710
- Local Institution
-
Monterrey, Nuevo LEON, Mexique, 64000
- Local Institution
-
Monterrey, Nuevo LEON, Mexique, 64700
- Local Institution
-
-
Sinaloa
-
Culiacan, Sinaloa, Mexique, 80020
- Local Institution
-
-
Veracruz
-
Jalapa, Veracruz, Mexique, 91020
- Local Institution
-
-
-
-
-
Alesund, Norvège, 6003
- Local Institution
-
Bergen, Norvège, 5021
- Local Institution
-
Bergen, Norvège, N-5021
- Local Institution
-
Elverum, Norvège, 2408
- Local Institution
-
Flekkefjord, Norvège, 4400
- Local Institution
-
Nesttun, Norvège, 5221
- Local Institution
-
Oslo, Norvège, 0407
- Local Institution
-
Skien, Norvège, 3710
- Local Institution
-
Stavanger, Norvège, 4064
- Local Institution
-
Straume, Norvège, 5353
- Local Institution
-
Tonsberg, Norvège, 3116
- Local Institution
-
Tromso, Norvège, 9038
- Local Institution
-
-
-
-
-
Breda, Pays-Bas, 4818 CK
- Local Institution
-
Deventer, Pays-Bas, 7416 SE
- Local Institution
-
Eindhoven, Pays-Bas, 5623 EJ
- Local Institution
-
Eindhoven, Pays-Bas, 5623EJ
- Local Institution
-
Enschede, Pays-Bas, 7513 ER
- Local Institution
-
Hardenberg, Pays-Bas, 7772 SE
- Local Institution
-
Hilversum, Pays-Bas, 1213 XZ
- Local Institution
-
Nijmegen, Pays-Bas, 6525 GA
- Local Institution
-
Oss, Pays-Bas, 5342 BT
- Local Institution
-
Rotterdam, Pays-Bas, 3045 PM
- Local Institution
-
S-Hertogenbosch, Pays-Bas, 5211 NL
- Local Institution
-
Tiel, Pays-Bas, 4002 WP
- Local Institution
-
Utrecht, Pays-Bas, 3582 KE
- Local Institution
-
Velp, Pays-Bas, 6883 AZ
- Local Institution
-
-
-
-
-
Manila, Philippines, 1000
- Local Institution
-
Manila, Philippines, 1008
- Local Institution
-
Naga City, Philippines, 4400
- Local Institution
-
Pasig City, Philippines, 1600
- Local Institution
-
Quezon, Philippines, 1100
- Local Institution
-
Quezon City, Philippines, 1102
- Local Institution
-
San Juan, Philippines, 1100
- Local Institution
-
-
Ilocos Norte
-
Laoag City, Ilocos Norte, Philippines, 2900
- Local Institution
-
-
-
-
-
Gdynia, Pologne, 81-423
- Local Institution
-
Gdynia, Pologne, 81-472
- Local Institution
-
Gdynia, Pologne, 81-519
- Local Institution
-
Grodzisk Mazowiecki, Pologne, 05-825
- Local Institution
-
Inowroclaw, Pologne, 88-100
- Local Institution
-
Kielce, Pologne, 25-736
- Local Institution
-
Kielce, Pologne, 25-763
- Local Institution
-
Krakow, Pologne, 31-202
- Local Institution
-
Krakow, Pologne, 30-092
- Local Institution
-
Krakow, Pologne, 31-135
- Local Institution
-
Lodz, Pologne, 91-347
- Local Institution
-
Lodz, Pologne, 91347
- Local Institution
-
Piotrkow Trybunalski, Pologne, 97-300
- Local Institution
-
Plock, Pologne, 09-402
- Local Institution
-
Plock, Pologne, 09-400
- Local Institution
-
Plonsk, Pologne, 09-100
- Local Institution
-
Poznan, Pologne, 60-531
- Local Institution
-
Poznan, Pologne, 60479
- Local Institution
-
Ruda Slaska, Pologne, 41-703
- Local Institution
-
Skierniewice, Pologne, 96-100
- Local Institution
-
Slupsk, Pologne, 76-200
- Local Institution
-
Torun, Pologne, 87100
- Local Institution
-
Warszawa, Pologne, 01-138
- Local Institution
-
Warszawa, Pologne, 04-073
- Local Institution
-
Warszawa, Pologne, 04-628
- Local Institution
-
Warszawa, Pologne, 04-749
- Local Institution
-
Wegrow, Pologne, 07100
- Local Institution
-
-
-
-
-
Cayey, Porto Rico, 00736
- Local Institution
-
Cidra, Porto Rico, 00739
- Local Institution
-
Ponce, Porto Rico, 00717
- Local Institution
-
-
-
-
-
Lima, Pérou, LIMA 33
- Local Institution
-
Lima, Pérou, LIMA 01
- Local Institution
-
Lima, Pérou, LIMA 1
- Local Institution
-
-
Callao
-
Bellavista, Callao, Pérou, 2176
- Local Institution
-
Bellavista, Callao, Pérou, CALLAO 2
- Local Institution
-
-
Lambayeque
-
Chiclayo, Lambayeque, Pérou, CIX
- Local Institution
-
-
Lima
-
Jesus Maria, Lima, Pérou, 11
- Local Institution
-
Jesus Maria, Lima, Pérou, LIMA 11
- Local Institution
-
Miraflores, Lima, Pérou, LIMA 18
- Local Institution
-
San Borja, Lima, Pérou, LIMA 41
- Local Institution
-
San Martin De Porres, Lima, Pérou, LIMA 31
- Local Institution
-
-
-
-
-
Baia Mare, Roumanie, 430031
- Local Institution
-
Bucharest, Roumanie, 011192
- Local Institution
-
Bucharest, Roumanie, 020125
- Local Institution
-
Bucharest, Roumanie, 050098
- Local Institution
-
Bucharest, Roumanie, 021659
- Local Institution
-
Bucharest, Roumanie, 030572
- Local Institution
-
Cluj Napoca, Roumanie, 400001
- Local Institution
-
Cluj Napoca, Roumanie, 400347
- Local Institution
-
Iasi, Roumanie, 700503
- Local Institution
-
Oradea, Roumanie, 410169
- Local Institution
-
Sibiu, Roumanie, 550245
- Local Institution
-
Targu-Mures, Roumanie, 540103
- Local Institution
-
Timisoara, Roumanie, 300024
- Local Institution
-
Timisoara, Roumanie, 300320
- Local Institution
-
Tirgu Mures, Roumanie, 540136
- Local Institution
-
-
-
-
-
Antrim, Royaume-Uni, BT41 2RL
- Local Institution
-
Blackpool, Royaume-Uni, FY3 8NR
- Local Institution
-
Glasgow, Royaume-Uni, G21 3UW
- Local Institution
-
-
Aberdeenshire
-
Aberdeen, Aberdeenshire, Royaume-Uni, AB25 2ZN
- Local Institution
-
Glasgow, Aberdeenshire, Royaume-Uni, G11 6NT
- Local Institution
-
-
Antrim
-
Belfast, Antrim, Royaume-Uni, BT14 6AB
- Local Institution
-
-
Armagh
-
Craigavon, Armagh, Royaume-Uni, BT63 5QQ
- Local Institution
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 2QQ
- Local Institution
-
Peterborough, Cambridgeshire, Royaume-Uni, PE2 5GP
- Local Institution
-
-
Derbyshire
-
Chesterfield, Derbyshire, Royaume-Uni, S44 5BL
- Local Institution
-
Chesterfield, Derbyshire, Royaume-Uni, S40 4TF
- Local Institution
-
-
Dorset
-
Bournemouth, Dorset, Royaume-Uni, BH7 7DW
- Local Institution
-
-
Dumbartonshire
-
Glasgow, Dumbartonshire, Royaume-Uni, G11 6NT
- Local Institution
-
-
EAST Sussex
-
Chichester, EAST Sussex, Royaume-Uni, PO19 6SE
- Local Institution
-
-
Essex
-
Colchester, Essex, Royaume-Uni, C03 4LN
- Local Institution
-
Romford, Essex, Royaume-Uni, RH7 0AG
- Local Institution
-
-
Greater London
-
Denmark Hill, Greater London, Royaume-Uni, SE5 9RS
- Local Institution
-
London, Greater London, Royaume-Uni, SW17 0RE
- Local Institution
-
-
Gwent
-
Newport, Gwent, Royaume-Uni, NP20 2UB
- Local Institution
-
-
Hertfordshire
-
Barnet, Hertfordshire, Royaume-Uni, EN5 3DJ
- Local Institution
-
-
MID Glamorgan
-
Cardiff, MID Glamorgan, Royaume-Uni, CF14 4XW
- Local Institution
-
Llandough, MID Glamorgan, Royaume-Uni, CF64 2XX
- Local Institution
-
-
Middlesex
-
Harrow, Middlesex, Royaume-Uni, HA1 3UJ
- Local Institution
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Royaume-Uni, NG5 1PB
- Local Institution
-
Worksop, Nottinghamshire, Royaume-Uni, S81 OBD
- Local Institution
-
-
Renfrewshire
-
Paisley, Renfrewshire, Royaume-Uni, PA2 9PN
- Local Institution
-
-
South Yorkshire
-
Barnsley, South Yorkshire, Royaume-Uni, S75 2EP
- Local Institution
-
Doncaster, South Yorkshire, Royaume-Uni, DN2 5LT
- Local Institution
-
-
Stirlingshire
-
Stirling, Stirlingshire, Royaume-Uni, FK8 2AU
- Local Institution
-
-
Strathclyde
-
Glasgow, Strathclyde, Royaume-Uni, G51 4TF
- Local Institution
-
-
Suffolk
-
Bury St Edmunds, Suffolk, Royaume-Uni, IP31 2HD
- Local Institution
-
Bury St Edmunds, Suffolk, Royaume-Uni, IP33 2QZ
- Local Institution
-
Bury St. Edmunds, Suffolk, Royaume-Uni, IP30 9QU
- Local Institution
-
Ipswich, Suffolk, Royaume-Uni, IP14 2PU
- Local Institution
-
Ipswich, Suffolk, Royaume-Uni, IP7 5DN
- Local Institution
-
-
Tyne and Wear
-
Newcastle Upon Tyne, Tyne and Wear, Royaume-Uni, NE1 4LP
- Local Institution
-
-
WEST Glamorgan
-
Swansea, WEST Glamorgan, Royaume-Uni, SA6 6NL
- Local Institution
-
-
WEST Lothian
-
Livingston, WEST Lothian, Royaume-Uni, EH54 6PP
- Local Institution
-
-
WEST Midlands
-
Birmingham, WEST Midlands, Royaume-Uni, B18 7QH
- Local Institution
-
-
Wiltshire
-
Westbury, Wiltshire, Royaume-Uni, BA 13 3JD
- Local Institution
-
Westbury, Wiltshire, Royaume-Uni, BA13 3JD
- Local Institution
-
-
Yorkshire
-
York, Yorkshire, Royaume-Uni, YO31 8HE
- Local Institution
-
York, Yorkshire, Royaume-Uni, YO31 HE
- Local Institution
-
-
-
-
-
Singapore, Singapour, 168752
- Local Institution
-
-
-
-
-
Baden, Suisse, 5404
- Local Institution
-
Bern, Suisse, 3010
- Local Institution
-
-
-
-
-
Goteberg, Suède, 413 45
- Local Institution
-
Helsingborg, Suède, 251 87
- Local Institution
-
Linkoping, Suède, 581 85
- Local Institution
-
Lund, Suède, 222 21
- Local Institution
-
Orebro, Suède, 70185
- Local Institution
-
Orebro, Suède, 701 85
- Local Institution
-
Skelleftea, Suède, 931 86
- Local Institution
-
Stockholm, Suède, 141 86
- Local Institution
-
Stockholm, Suède, 171 76
- Local Institution
-
Stockholm, Suède, 111 57
- Local Institution
-
Stockholm, Suède, 118 83
- Local Institution
-
Stockholm, Suède, 111 35
- Local Institution
-
Uppsala, Suède, 751 85
- Local Institution
-
Vaxjo, Suède, 351 85
- Local Institution
-
-
-
-
-
Taipei, Taïwan, 100
- Local Institution
-
Taipei, Taïwan, 112
- Local Institution
-
Taipei, Taïwan, 111
- Local Institution
-
Taipei, Taïwan, 220
- Local Institution
-
Taipei, Taïwan, 10449
- Local Institution
-
Taipei, Taïwan, 104
- Local Institution
-
-
-
-
-
Boskovice, Tchéquie, 680 21
- Local Institution
-
Brno, Tchéquie, 625 00
- Local Institution
-
Brno-Malomerice, Tchéquie, 614 00
- Local Institution
-
Ivancice, Tchéquie, 664 91
- Local Institution
-
Kladno, Tchéquie, 272 59
- Local Institution
-
Litomysl, Tchéquie, 570 14
- Local Institution
-
Mestec Kralove, Tchéquie, 289 03
- Local Institution
-
Ostrava, Tchéquie, 70852
- Local Institution
-
Prague 13, Tchéquie, 158 00
- Local Institution
-
Prague 2, Tchéquie, 128 08
- Local Institution
-
Pribram, Tchéquie, 261 01
- Local Institution
-
Usti Nad Orlici, Tchéquie, 562 18
- Local Institution
-
-
-
-
-
Ankara, Turquie, 06100
- Local Institution
-
Eskisehir, Turquie, 26480
- Local Institution
-
Izmir, Turquie, 35100
- Local Institution
-
-
-
-
-
Chernivtsy, Ukraine, 58013
- Local Institution
-
Dnipropetrovsk, Ukraine, 49006
- Local Institution
-
Dnipropetrovsk, Ukraine, 49060
- Local Institution
-
Donetsk, Ukraine, 83045
- Local Institution
-
Donetsk, Ukraine, 83003
- Local Institution
-
Donetsk, Ukraine, 83114
- Local Institution
-
Ivano-Frankivsk, Ukraine, 76025
- Local Institution
-
Kharkiv, Ukraine, 61018
- Local Institution
-
Kharkiv, Ukraine, 61115
- Local Institution
-
Kharkov, Ukraine, 61039
- Local Institution
-
Kharkov, Ukraine, 61002
- Local Institution
-
Kharkov, Ukraine, 61178
- Local Institution
-
Kiev, Ukraine, 01032
- Local Institution
-
Kyiv, Ukraine, 03680
- Local Institution
-
Kyiv, Ukraine, 02091
- Local Institution
-
Kyiv, Ukraine, 03049
- Local Institution
-
Kyiv, Ukraine, 03115
- Local Institution
-
Kyiv, Ukraine, 04050
- Local Institution
-
Kyiv, Ukraine, 04107
- Local Institution
-
Kyiv, Ukraine, 01023
- Local Institution
-
Kyiv, Ukraine, 02660
- Local Institution
-
Kyiv, Ukraine, 01103
- Local Institution
-
Lugansk, Ukraine, 91011
- Local Institution
-
Lugansk, Ukraine, 91016
- Local Institution
-
Lutsk, Ukraine, 43024
- Local Institution
-
Lviv, Ukraine, 79013
- Local Institution
-
Lviv, Ukraine, 79015
- Local Institution
-
Mykolayiv, Ukraine, 54003
- Local Institution
-
Odessa, Ukraine, 65009
- Local Institution
-
Odessa, Ukraine, 65039
- Local Institution
-
Odessa, Ukraine, 65114
- Local Institution
-
Odessa, Ukraine, 65025
- Local Institution
-
Uzhgorod, Ukraine, 88000
- Local Institution
-
Vinnitsa, Ukraine, 21029
- Local Institution
-
Zaporozhye, Ukraine, 69035
- Local Institution
-
Zhytomyr, Ukraine, 10002
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35209
- Cardiovascular Associates, Pc
-
Birmingham, Alabama, États-Unis, 35235
- Alabama Internal Medicine Pc
-
Birmingham, Alabama, États-Unis, 35235
- Birmingham Heart Clinic P.C.
-
Huntsville, Alabama, États-Unis, 35801
- Heart Center, Inc.
-
Mobile, Alabama, États-Unis, 36608
- Mobile Heart Specialists, PC
-
Mobile, Alabama, États-Unis, 36617
- Clara V. Massey, Md
-
-
Alaska
-
Anchorage, Alaska, États-Unis, 99508
- Alaska Heart Institute
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006
- Internal Medicine Physicians Associates, P.C.
-
Tucson, Arizona, États-Unis, 85723
- Southern Arizona VA Health Care System
-
Tucson, Arizona, États-Unis, 85710
- Southwest Heart
-
Tucson, Arizona, États-Unis, 85745
- Pima Research Foundation
-
-
Arkansas
-
Hot Springs, Arkansas, États-Unis, 71913
- Dr. Rajesh Shroff
-
Little Rock, Arkansas, États-Unis, 72204
- Mary K. Richards, Md Pa
-
-
California
-
Anaheim, California, États-Unis, 92801
- Advanced Clinical Reserach Institute
-
Beverly Hills, California, États-Unis, 90210
- Act/Cardiovascular Research Institute
-
Carmichael, California, États-Unis, 95608
- Capitol Interventional Cardiology
-
Escondido, California, États-Unis, 92025
- Escondido Cardiology Associates, Inc.
-
Healdsburg, California, États-Unis, 95448
- William D. Bowden, D.O.
-
La Mesa, California, États-Unis, 91942
- La Mesa Cardiac Center, A Medical Group
-
Los Angeles, California, États-Unis, 90073
- VA Greater Los Angeles Healthcare System
-
Mission Viejo, California, États-Unis, 92691
- Coastal Cardiology
-
Oceanside, California, États-Unis, 92056
- Kenneth W. Carr Md
-
Palm Springs, California, États-Unis, 92262
- Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
-
Rancho Mirage, California, États-Unis, 92270
- Desert Cardiology Consultants Medical Group, Inc
-
Sacramento, California, États-Unis, 95821
- Northern California Research
-
Sacramento, California, États-Unis, 95825
- Sacramento Heart And Vascular Medical Associates
-
Sacramento, California, États-Unis, 95819
- Regional Cardiolody Associates
-
Santa Barbara, California, États-Unis, 93105
- Arrhythmia Consultants Of The Central Coast Medical Group
-
Santa Rosa, California, États-Unis, 95403
- Northern California Medical Associates
-
Vista, California, États-Unis, 92083
- Progressive Clinical Research
-
Walnut Creek, California, États-Unis, 94598
- Cardivasclular Consultants Medical Group
-
Wildomar, California, États-Unis, 92595
- Shiva Heart Center Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80910
- Electrophysiology Associates, Pc
-
Denver, Colorado, États-Unis, 80220
- Denver VA Medical Center
-
Denver, Colorado, États-Unis, 80218
- Aurora Denver Cardiology Associates, P.C.
-
Golden, Colorado, États-Unis, 80401
- New West Physicians Clinical Research
-
Littleton, Colorado, États-Unis, 80120
- South Denver Cardiology Associates PC
-
-
Connecticut
-
Bridgeport, Connecticut, États-Unis, 06610
- Bridgeport Hospital
-
Bridgeport, Connecticut, États-Unis, 06606
- Connecticut Clinical Research, Llc
-
Guilford, Connecticut, États-Unis, 06437
- Cardiology Associates Of New Haven,Pc
-
Norwich, Connecticut, États-Unis, 06360
- William W Backus Hospital
-
Norwich, Connecticut, États-Unis, 06360
- The William W. Backus Hospital
-
Stamford, Connecticut, États-Unis, 06905
- Stamford Therapeutics Consortium
-
Waterbury, Connecticut, États-Unis, 06708
- Chase Medical Research, LLC
-
-
Delaware
-
Newark, Delaware, États-Unis, 19713
- Alfieri Cardiology
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20422
- Washington VA Medical Center
-
Washington, District of Columbia, États-Unis, 20037
- George Washington University Medical Faculty Associates
-
-
Florida
-
Atlantis, Florida, États-Unis, 33462
- Medical Specialist Of The Palm Beach
-
Aventura, Florida, États-Unis, 33180
- Miami International Cardiology Consultants
-
Boca Raton, Florida, États-Unis, 33431
- David Charles Mishkel, Md, Pa
-
Clearwater, Florida, États-Unis, 33756
- The Heart & Vascular Institute Of Florida
-
Clearwater, Florida, États-Unis, 33756
- The Heart And Vascular Institute Of Florida
-
Davie, Florida, États-Unis, 33324
- Cardiovascular Specialist Of South Florida
-
Daytona Beach, Florida, États-Unis, 32114
- Daytona Heart Group
-
Fort Lauderdale, Florida, États-Unis, 33316
- Broward General Medical Center
-
Fort Lauderdale, Florida, États-Unis, 33308
- Cardiology Associates Of Fort Lauderdale, P.A.
-
Fort Myers, Florida, États-Unis, 33907
- Florida Heart Associates
-
Gainesville, Florida, États-Unis, 32605
- Florida Research Network, LLC
-
Hollywood, Florida, États-Unis, 33021
- Healthworx
-
Hollywood, Florida, États-Unis, 33021
- Luis Tami, Md
-
Inverness, Florida, États-Unis, 34452
- Nature Coast Clinical Research
-
Jacksonville, Florida, États-Unis, 32216
- Jacksonville Center for Clinical Research
-
Jacksonville, Florida, États-Unis, 32216
- Jacksonville Cardiovascular Center
-
Jacksonville, Florida, États-Unis, 32258
- Jacksonville Heart Center, Pa
-
Jacksonville, Florida, États-Unis, 32204
- St. Vincent'S Ambulatory Care, Inc
-
Jacksonville, Florida, États-Unis, 32207
- Jacksonville Heart Center, Pa
-
Jacksonville, Florida, États-Unis, 32216
- St. Luke'S Cardiology
-
Jacksonville Beach, Florida, États-Unis, 32250
- Jacksonville Heart Center, P.A.
-
Jupiter, Florida, États-Unis, 33458
- Cvms Research Institute, Llc
-
Jupiter, Florida, États-Unis, 33458
- Ricardo Bedoya, M.D.
-
Melbourne, Florida, États-Unis, 32901
- Melbourne Internal Medicine Associates
-
Miami, Florida, États-Unis, 33137
- Miami International Cardiology Consultants
-
Miami, Florida, États-Unis, 33137-3732
- Miami International Cardiology Consultants
-
Naples, Florida, États-Unis, 34119
- Physicians Regional Medical Group
-
Orlando, Florida, États-Unis, 32803
- Florida Heart Group
-
Oviedo, Florida, États-Unis, 32765
- Alpha Medical Research
-
Pensacola, Florida, États-Unis, 32501
- Cardiology Consultants
-
Saint Petersburg, Florida, États-Unis, 33709
- The Heart And Vascular Institute Of Florida
-
Sarasota, Florida, États-Unis, 34239
- Heart & Vascular Center Research, Inc.
-
Sarasota, Florida, États-Unis, 34232
- Niranjan Seshadri, Md
-
Vero Beach, Florida, États-Unis, 32960
- Research, Inc.
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30342
- Cardiovascular Specialits, Pc
-
Augusta, Georgia, États-Unis, 30901
- Augusta Cardiology Clinic, P.C.
-
Columbus, Georgia, États-Unis, 31909
- Columbus Cardiology Associates Pc
-
Columbus, Georgia, États-Unis, 31909
- Columbus Cardiology Associates,Pc
-
Covington, Georgia, États-Unis, 30014
- Georgia Heart Specialists, L.L.C.
-
Decatur, Georgia, États-Unis, 30030
- Atlanta Institute For Medical Research, Inc
-
Gainesville, Georgia, États-Unis, 30501
- Northeast Georgia Heart Center, Pc
-
Marietta, Georgia, États-Unis, 30060
- Wellstar Cardiovascular Medicine, Pc
-
-
Illinois
-
Aurora, Illinois, États-Unis, 60504
- Fox Valley Clinical Research Center, LLC
-
Chicago, Illinois, États-Unis, 60611
- Nmff
-
Gurnee, Illinois, États-Unis, 60031
- Clinical Investigation Specialists, Inc
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center
-
Normal, Illinois, États-Unis, 61761
- Illinois Heart & Lung Research Center, Sc
-
North Chicago, Illinois, États-Unis, 60064
- Cpt. James A Lovell Federal Health Care Center
-
-
Indiana
-
Anderson, Indiana, États-Unis, 46011
- Community Clinical Research Center
-
Bloomington, Indiana, États-Unis, 47403
- Premier Healthcare, Llc
-
Elkhart, Indiana, États-Unis, 46514
- Elkhart Clinic, LLC
-
Fort Wayne, Indiana, États-Unis, 46804
- Lutheran Medical Group, Llc
-
Fort Wayne, Indiana, États-Unis, 46805
- Fort Wayne Cardiology
-
Indianapolis, Indiana, États-Unis, 46290
- The Care Group, Llc
-
Indianapolis, Indiana, États-Unis, 46290
- The Care Group, Llc.
-
Indianapolis, Indiana, États-Unis, 46237
- St Francis Medical Group - Indiana Heart Physicians
-
Michigan City, Indiana, États-Unis, 46360
- Dali, Sammi
-
South Bend, Indiana, États-Unis, 46601
- Cardiology Associates, Inc.
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- McFarland Clinic PC
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66209
- Midwest Cardiology Associates , P.C.
-
-
Kentucky
-
Elizabethtown, Kentucky, États-Unis, 42701
- Central Cardiology Assoc.
-
Lexington, Kentucky, États-Unis, 40504
- New Lexington Clinic, P.S.C.
-
Louisville, Kentucky, États-Unis, 40205
- Norton Cardiovascular Associates
-
Louisville, Kentucky, États-Unis, 40202
- VA Medical Center
-
Owensboro, Kentucky, États-Unis, 42303
- Owensboro Heart & Vascular
-
-
Louisiana
-
Alexandria, Louisiana, États-Unis, 71301
- Alexandria Cardiology Clinic
-
Houma, Louisiana, États-Unis, 70360
- Cardiovascular Institute of the South
-
Lacombe, Louisiana, États-Unis, 70445
- Smith, Patel & Amkieh, Llc
-
Lake Charles, Louisiana, États-Unis, 70601
- Imperial Calcasieu Medical Group, Llp
-
Marrero, Louisiana, États-Unis, 70072
- Cardiology Center, Llc
-
Shreveport, Louisiana, États-Unis, 71105
- Cardiology Associates
-
Slidell, Louisiana, États-Unis, 70458
- Louisiana Heart Center
-
Slidell, Louisiana, États-Unis, 70458
- Medical Research Inst, Inc
-
Slidell, Louisiana, États-Unis, 70458
- Medical Research Institute, Inc
-
Ventura, Louisiana, États-Unis, 93003
- Ventura Cardio. Cond. Med. Group, Inc.
-
-
Maine
-
Lewiston, Maine, États-Unis, 04240
- Central Maine Heart & Vascular Institute
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, États-Unis, 21237
- Franklin Square Hospital
-
Baltimore, Maryland, États-Unis, 21208
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore, Maryland, États-Unis, 21237
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore, Maryland, États-Unis, 21204
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore, Maryland, États-Unis, 21218
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore, Maryland, États-Unis, 21224-2735
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, États-Unis, 21237
- Midatlantic Cardiovascular Associates, P.A.
-
Bel Air, Maryland, États-Unis, 21014
- Midatlantic Cardiovascular Associates, Pa
-
Columbia, Maryland, États-Unis, 21044
- Cardiovascular Specialists Of Central Maryland, P.A.
-
Reisterstown, Maryland, États-Unis, 21136
- Clinical Associates Research
-
Westminster, Maryland, États-Unis, 21157
- Midatlantic Cardiovascular Associates, Pa
-
-
Massachusetts
-
Billerica, Massachusetts, États-Unis, 01821
- Burlington Medical Associates
-
Boston, Massachusetts, États-Unis, 02135
- Caritas St. Elizabeth's Medical Center
-
Burlington, Massachusetts, États-Unis, 01805
- Lahey Clinic Medical Center
-
Fall River, Massachusetts, États-Unis, 02720
- Neccr Internal Medicine & Cardiology Associates,Llc
-
Haverhill, Massachusetts, États-Unis, 01830
- Pentucket Medical Associates
-
Haverhill, Massachusetts, États-Unis, 01830-6278
- Pentucket Medical Associates
-
Natick, Massachusetts, États-Unis, 01760
- Charles River Medical Associates
-
-
Michigan
-
Alpena, Michigan, États-Unis, 49707
- Great Lakes Heart Center Of Alpena
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
Lansing, Michigan, États-Unis, 48910
- Thoracic And Cardiovascular Healthcare Foundation
-
Livonia, Michigan, États-Unis, 48154
- Advanced Cardiovascular Health Specialists, Pc
-
Petoskey, Michigan, États-Unis, 49770
- Michigan Heart And Vascular Specialists
-
Royal Oak, Michigan, États-Unis, 48073
- William Beaumont Hospital
-
Ypsilanti, Michigan, États-Unis, 48197
- Michigan Heart, P.C.
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota
-
Minneapolis, Minnesota, États-Unis, 55417
- Minneapolis VA Medical Center
-
Robbinsdale, Minnesota, États-Unis, 55422
- North Memorial Health Care
-
-
Mississippi
-
Olive Branch, Mississippi, États-Unis, 38654
- Olive Branch Family Medical Center
-
Tupelo, Mississippi, États-Unis, 38801
- Tupelo Neurology Clinic, Pa
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65212
- University of Missouri
-
Kansas City, Missouri, États-Unis, 64108
- Truman Medical Center
-
Kansas City, Missouri, États-Unis, 64111
- Saint Luke's Lipid and Diabetes Research Center
-
-
Nebraska
-
Grand Island, Nebraska, États-Unis, 68803
- Internal Medical Associates Of Grand Island, P.C
-
Grand Island, Nebraska, États-Unis, 68803-4311
- Internal Medical Associates Of Grand Island, P.C
-
Hastings, Nebraska, États-Unis, 68901
- Nebraska Heart Institute
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89106
- VA Southern Nevada Healthcare System
-
-
New Jersey
-
Berlin, New Jersey, États-Unis, 08009
- Comprehensive Clinical Research
-
Elmer, New Jersey, États-Unis, 08318
- Cardiovascular Associates Of The Delware Valley, P.A.
-
Haddon Heights, New Jersey, États-Unis, 08035
- Cardiovascular Associates Of The Delaware Valley, P.A.
-
Princeton, New Jersey, États-Unis, 08540
- Princeton Medical Institute
-
Sewell, New Jersey, États-Unis, 08080
- Cardio Assoc Of Del Val, P.A.
-
South Plainfield, New Jersey, États-Unis, 07080
- Central New Jersey Cardiology
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87012
- Abq Health Partners, Llc
-
Albuquerque, New Mexico, États-Unis, 87131-0001
- University Of New Mexico/University Hospital
-
Albuquerque, New Mexico, États-Unis, 87131
- University Of New Mexico/University Hospital
-
-
New York
-
Albany, New York, États-Unis, 12205
- Albany Associates in Cardiology
-
Albany, New York, États-Unis, 12205
- Albany Assoc. In Cardiology
-
Binghamton, New York, États-Unis, 13905
- Cardiology Associates, Pc
-
Buffalo, New York, États-Unis, 14215
- Buffalo Heart Group, LLP
-
Buffalo, New York, États-Unis, 14215-1145
- Buffalo Heart Group, LLP
-
Buffalo, New York, États-Unis, 14215
- Bruce L. Platt Md, Pc
-
Buffalo, New York, États-Unis, 14215
- Bruce L. Platt, Md
-
East Syracuse, New York, États-Unis, 13057
- Heart Care Center, P.C.
-
Huntington, New York, États-Unis, 11743
- Huntington Hospital
-
Liverpool, New York, États-Unis, 13088
- SJH Cardiology Associates
-
Mineola, New York, États-Unis, 11501
- Long Island Heart Associates
-
Saratoga Springs, New York, États-Unis, 12866
- Saratoga Cardiology Associates, Pc
-
Williamsville, New York, États-Unis, 14221
- Office Of Dr. Kozinn
-
Williamsville, New York, États-Unis, 14221
- Suburban Cardiology
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28803
- Asheville Cardiology Associates
-
Burlington, North Carolina, États-Unis, 27215
- Kernodle Clinic, Inc.
-
High Point, North Carolina, États-Unis, 27262
- Carolina Cardiology Associates, Pa
-
Pinehurst, North Carolina, États-Unis, 28374
- Pinehurst Medical Center, Inc
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58103
- Lillestol Research LLC
-
-
Ohio
-
Akron, Ohio, États-Unis, 44304
- Akron Cardiology Consultants
-
Bucyrus, Ohio, États-Unis, 44820
- Christopher M. Johnson, D.O.
-
Bucyrus, Ohio, États-Unis, OHIO
- Christopher M. Johnson, D.O.
-
Canal Fulton, Ohio, États-Unis, 44614
- Community Health Care, Inc.
-
Canton, Ohio, États-Unis, 44710
- Cardiology Associates
-
Cincinnati, Ohio, États-Unis, 45219
- The Carl & Edyth Lindner Center For R&E At The Christ Hosp
-
Toledo, Ohio, États-Unis, 43608
- Toledo Cardiology Consultants
-
Wadsworth, Ohio, États-Unis, 44281
- Family Practice Center Of Wadsworth, Inc.
-
-
Oklahoma
-
Muskogee, Oklahoma, États-Unis, 74401
- Jack C. Va Medical Center
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, États-Unis, 73112
- Plaza Medical Group, Pc
-
Oklahoma City, Oklahoma, États-Unis, 73103
- COR Clinical Research, LLC
-
Oklahoma City, Oklahoma, États-Unis, 73135
- South Oklahoma Heart Research
-
Oklahoma City, Oklahoma, États-Unis, 73120
- Oklahoma Heart Hospital Physicians
-
Oklahoma City, Oklahoma, États-Unis, 73139
- Eminence Research, LLC
-
Tulsa, Oklahoma, États-Unis, 74136
- Castlerock Clinical Research Consultants, Llc
-
-
Oregon
-
Bend, Oregon, États-Unis, 97701
- St. Charles Health System, Inc.
-
Bend, Oregon, États-Unis, 97701
- St. Charles Health System, Inc
-
Eugene, Oregon, États-Unis, 97401
- Oregon Medical Group - Clinical Research
-
Hillsboro, Oregon, États-Unis, 97123
- Hillsboro Cardiology Pc
-
Medford, Oregon, États-Unis, 97504
- Rogue Valley Physicians - Clinical Research Group
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Abington Medical Specialists
-
Altoona, Pennsylvania, États-Unis, 16602
- Blair Medical Associates, Inc.
-
Camp Hill, Pennsylvania, États-Unis, 17011
- Heritage Cardiology Assoc.
-
Doylestown, Pennsylvania, États-Unis, 18901
- Central Bucks Cardiology
-
Erie, Pennsylvania, États-Unis, 16509
- Internal Medicine And Lipid Mgmt.
-
Harrisburg, Pennsylvania, États-Unis, 17112
- Kandra, Fierer, Kuskin Associates
-
Hatfield, Pennsylvania, États-Unis, 19440
- Pivotal Clinical Research, Llc
-
Jersey Shore, Pennsylvania, États-Unis, 17740
- Lycoming Internal Medicine Inc.
-
Sayre, Pennsylvania, États-Unis, 18840
- Guthrie Medical Group, P.C.
-
Sayre, Pennsylvania, États-Unis, 18840
- Guthrie Clinic Ltd.
-
Uniontown, Pennsylvania, États-Unis, 15401
- Preferred Primary Care Physicians
-
West Chester, Pennsylvania, États-Unis, 19380
- West Chester Cardiology, Pc
-
Yardley, Pennsylvania, États-Unis, 19067
- Cardiology Consultants of Philadelphia
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Anderson, South Carolina, États-Unis, 29621
- Southeastern Research Associates, Inc
-
Beaufort, South Carolina, États-Unis, 29906
- Lowcountry Medical Group, Llc
-
Beaufort, South Carolina, États-Unis, 29906
- Lowcountry Medical Group
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, États-Unis, 29203
- Columbia Heart Clinic
-
Greenville, South Carolina, États-Unis, 29607
- Upstate Cardiology
-
Greer, South Carolina, États-Unis, 29650
- Internal Medicine Of Greer
-
Orangeburg, South Carolina, États-Unis, 29118
- Palmetto Nephrology Pa
-
Spartanburg, South Carolina, États-Unis, 29303
- S. Carolina Pharmaceutical Research
-
-
South Dakota
-
Pierre, South Dakota, États-Unis, 57501
- Avera Medical Associates Clinic
-
-
Tennessee
-
Bristol, Tennessee, États-Unis, 37620
- Holston Medical Group
-
Kingsport, Tennessee, États-Unis, 37660
- Holston Medical Group
-
Knoxville, Tennessee, États-Unis, 37920
- Volunteer Research Group
-
Knoxville, Tennessee, États-Unis, 37916
- Knoxville Heart Group
-
Knoxville, Tennessee, États-Unis, 37920-1502
- Volunteer Research Group
-
Tullahoma, Tennessee, États-Unis, 37388
- Tennessee Center For Clinical Trials
-
-
Texas
-
Amarillo, Texas, États-Unis, 79106
- Amarillo Heart Clinical Research Institute Inc.
-
Corsicana, Texas, États-Unis, 75110
- Corsicana Medical Research, PLLC
-
Dallas, Texas, États-Unis, 75226
- Soltero Cardiovascular Research Center
-
Dallas, Texas, États-Unis, 75230
- HeartPlace
-
Fort Worth, Texas, États-Unis, 76104
- Heart Center of North Texas
-
Houston, Texas, États-Unis, 77030
- The Methodist Hospital
-
Houston, Texas, États-Unis, 77030
- The University of Texas MD Anderson Cancer Center
-
Houston, Texas, États-Unis, 77030
- Center For Atrial Fibrillation
-
Houston, Texas, États-Unis, 77030
- The Methodist Hospital Neurology Institute
-
Houston, Texas, États-Unis, 77065
- Northwest Houston Cardiology, Pa
-
Houston, Texas, États-Unis, 77070
- Northwest Houston Cardiology, Pa
-
Houston, Texas, États-Unis, 77074
- Francisco R. Maislos
-
Houston, Texas, États-Unis, 77090
- Woodlands North Houston Heart Center
-
Humble, Texas, États-Unis, 77338
- Regional Medical Center And Diagnostic Clinics
-
Lackland Air Force Base, Texas, États-Unis, 78236
- Wilford Hall Medical Center
-
Lackland Air Force Base, Texas, États-Unis, 78236-9908
- Wilford Hall Medical Center
-
Longview, Texas, États-Unis, 75605
- DCOL Center for Clinical Research
-
McKinney, Texas, États-Unis, 75069
- North Dallas Research Associates
-
Plano, Texas, États-Unis, 75093
- North Texas Medical Research
-
Plano, Texas, États-Unis, 75024
- Legacy Heart Center
-
San Antonio, Texas, États-Unis, 78229
- Covenant Clinical Research, Pa
-
San Antonio, Texas, États-Unis, 78217
- Bhs Specialty Network, Inc
-
San Antonio, Texas, États-Unis, 78229
- Star Clinical Trails
-
Seguin, Texas, États-Unis, 78155
- Edward Balli, Md, Pa
-
Tomball, Texas, États-Unis, 77375
- Northwest Heart Center
-
Tyler, Texas, États-Unis, 75701
- Tyler Cardiovascular Consultants
-
Tyler, Texas, États-Unis, 75708
- University of Texas Health Science Center at Tyler
-
Tyler, Texas, États-Unis, 75708
- The Univ. Of Texas Health Science Ctr. At Tyler
-
-
Utah
-
Layton, Utah, États-Unis, 84041
- Utah Cardiology P.C
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23510
- Sentara York Clinical Research
-
Richmond, Virginia, États-Unis, 23220
- Medical Research Initiatives
-
Roanoke, Virginia, États-Unis, 24014
- Roanoke Heart Institute, Plc
-
Virginia Beach, Virginia, États-Unis, 23454
- Cardiovascular Associates
-
-
Washington
-
Burien, Washington, États-Unis, 98166
- Daniel W. Gottlieb, Md, Ps
-
Burien, Washington, États-Unis, 98166
- Daniel William Gottlieb, Md
-
Spokane, Washington, États-Unis, 99202
- Rockwood Clinic Research Cent.
-
Walla Walla, Washington, États-Unis, 99362
- Walla Walla Clinic
-
-
West Virginia
-
Lewisburg, West Virginia, États-Unis, 24901
- Lynn N. Smith, Md
-
-
Wisconsin
-
Green Bay, Wisconsin, États-Unis, 54301
- Cardiology Associates Of Green Bay Ltd-Bellin Hospital
-
Madison, Wisconsin, États-Unis, 53715
- St. Mary's Hospital
-
Madison, Wisconsin, États-Unis, 53715
- St.Mary's Hospital
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53215
- Aurora Health Care
-
Waukesha, Wisconsin, États-Unis, 53188
- Cardiology Assc. Of Waukesha
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
- Age ≥ 75, previous stroke
- transient ischemic attack (TIA) or Systemic Embolism (SE)
- Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%
- Diabetes mellitus or hypertension requiring pharmacological treatment
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 2
|
Oral tablets, 5.0 mg or 2.5 mg, twice daily
Autres noms:
|
Comparateur actif: 1
|
Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
Délai: Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
All suspected efficacy events were adjudicated by the Central Events Committee (CEC).
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate=Number of adjudicated stroke or SE events per 100 patient years.
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years.
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Number of Participants With Events of All-Cause Death During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Death was defined as all-cause mortality.
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate of Adjudicated All-Cause Death During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of ACD, see Outcome Measure 5.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of Major bleeding, see Outcome Measure 3.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
Délai: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death.
CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of major or CRNM bleed events per 100 patient years.
Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death.
CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Number of Participants With All Bleeding Events During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of All Bleeding Events During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of all bleeding events per 100 patient years.
"All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD).
SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD.
Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD.
Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued.
Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated GUSTO bleeding events per 100 patient years.
GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention.
GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated TIMI bleeding events per 100 patient years.
TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions.
Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Number of Participants With Net-Clinical Benefit During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate of Net-Clinical Benefit During Treatment Period
Délai: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of events of net-clinical benefit per 100 patient years.
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.
- Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
- Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
- Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
- Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
- Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
- Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.
- Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Wallentin L. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020 Sep 15;9(18):e017155. doi: 10.1161/JAHA.120.017155. Epub 2020 Aug 31.
- Zeitouni M, Giczewska A, Alexander JH. Reply: Specifics of Dose Modification in ARISTOTLE. J Am Coll Cardiol. 2020 Jul 7;76(1):128-129. doi: 10.1016/j.jacc.2020.05.013. No abstract available.
- Rosjo H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, Gersh BJ, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 Aug;288(2):248-259. doi: 10.1111/joim.13072. Epub 2020 May 18.
- Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020 Mar 17;75(10):1145-1155. doi: 10.1016/j.jacc.2019.12.060.
- Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12.
- Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020 Mar;221:1-8. doi: 10.1016/j.ahj.2019.10.013. Epub 2019 Oct 31.
- Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-20. doi: 10.1161/CIRCULATIONAHA.119.041296. Epub 2019 Nov 21.
- Goldstein SA, Green J, Huber K, Wojdyla DM, Lopes RD, Alexander JH, Vinereanu D, Wallentin L, Granger CB, Al-Khatib SM. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). Am J Cardiol. 2019 Nov 1;124(9):1406-1412. doi: 10.1016/j.amjcard.2019.07.046. Epub 2019 Aug 7.
- Guimaraes PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
- Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y.
- Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
- Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22.
- Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.
- Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.
- Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058.
- Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
- Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018 Mar;197:133-141. doi: 10.1016/j.ahj.2017.11.005. Epub 2017 Nov 10.
- Pol T, Held C, Westerbergh J, Lindback J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018 Feb 1;7(3):e007444. doi: 10.1161/JAHA.117.007444.
- Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75-81. doi: 10.1093/ehjcvp/pvy002.
- Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, Alexander JH. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018 Aug;104(15):1292-1299. doi: 10.1136/heartjnl-2017-312272. Epub 2018 Jan 19.
- Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 Mar;131(3):269-275.e2. doi: 10.1016/j.amjmed.2017.10.036. Epub 2017 Nov 6.
- Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266-3273. doi: 10.1161/STROKEAHA.117.017574. Epub 2017 Oct 31.
- Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6):e004851. doi: 10.1161/JAHA.116.004851.
- Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E Silva P, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980-2987. doi: 10.1182/blood-2016-08-731638. Epub 2017 Mar 29.
- Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065.
- Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1):e004699. doi: 10.1161/JAHA.116.004699.
- Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24.
- Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.
- Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016 Jul 1;1(4):451-60. doi: 10.1001/jamacardio.2016.1170.
- Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868.
- Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508-17. doi: 10.1136/heartjnl-2015-308887. Epub 2016 Feb 2.
- Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002015. doi: 10.1161/JAHA.115.002015. Erratum In: J Am Heart Assoc. 2021 Feb 16;10(4):e014653.
- Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447. Epub 2015 Sep 14.
- Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23.
- Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264-72. doi: 10.1093/eurheartj/ehu463. Epub 2014 Dec 12.
- Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb;61(2):368-78. doi: 10.1373/clinchem.2014.226936. Epub 2014 Dec 1.
- Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692-8. doi: 10.1182/blood-2014-08-595496. Epub 2014 Oct 15.
- Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204. Epub 2014 Oct 7.
- Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34. doi: 10.1161/CIRCULATIONAHA.113.006286. Epub 2013 Nov 13.
- Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB; ARISTOTLE Investigators. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19.
- Alexander JH, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, Califf RM, Wallentin L, Granger CB. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J. 2013 Sep;166(3):559-65. doi: 10.1016/j.ahj.2013.05.025. Epub 2013 Aug 15.
- Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.
- Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2.
- McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451-60. doi: 10.1161/CIRCHEARTFAILURE.112.000143. Epub 2013 Apr 10.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3.
- Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum In: Lancet. 2013 Jan 19;381(9862):204.
- Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum In: Lancet Neurol. 2012 Dec;11(12):1021.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
Liens utiles
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
31 décembre 2006
Achèvement primaire (Réel)
25 mai 2011
Achèvement de l'étude (Réel)
25 mai 2011
Dates d'inscription aux études
Première soumission
18 décembre 2006
Première soumission répondant aux critères de contrôle qualité
18 décembre 2006
Première publication (Estimation)
19 décembre 2006
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
3 juillet 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 juin 2018
Dernière vérification
1 mai 2018
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies cardiaques
- Maladies cardiovasculaires
- Arythmies cardiaques
- Fibrillation auriculaire
- Flutter auriculaire
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Inhibiteurs de protéase
- Inhibiteurs du facteur Xa
- Antithrombines
- Inhibiteurs de la sérine protéinase
- Anticoagulants
- Apixaban
- Warfarine
Autres numéros d'identification d'étude
- CV185-030
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .